GlassScriptPhysician profile
Joseph Sams
NPI 1912978255
$3,171.02
in general payments reported to CMS, 2019-2025
27 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $156 · 2021: $284 · 2022: $493 · 2023: $373 · 2024: $531 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Travel and Lodging: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.31 |
| Travel and Lodging | $315.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $908.21 | 2019-2025 | |
| Axonics, INC. | $249.05 | 2022-2024 | Axonics |
| Astellas Pharma US INC | $188.04 | 2023-2025 | Veozah |
| Pacira Pharmaceuticals Incorporated | $175.97 | 2019-2020 | |
| Biogen, INC. | $168.78 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $164.73 | 2022-2025 | |
| Abbvie INC. | $162.25 | 2022-2025 | Liletta |
| Exeltis, USA INC. | $157.83 | 2020-2025 | Slynd |
| Ethicon US, LLC | $141.31 | 2019-2022 | |
| Mindray Ds USA, INC. | $112.17 | 2021 | |
| Hologic Sales and Service, LLC | $110.42 | 2023-2024 | Acessa Provu System, Novasure, Omni Hysteroscope |
| Medical Device Business Services, INC. | $91.06 | 2021 | |
| Daiichi Sankyo INC. | $90.83 | 2019-2024 | Injectafer |
| Mayne Pharma Commercial LLC | $72.04 | 2022-2025 | |
| Organon LLC | $63.92 | 2022-2025 | Nexplanon, Jada System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.48 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $52.20 | 2021-2022 | |
| Pfizer INC. | $29.82 | 2024-2025 | |
| Millicent US INC | $29.27 | 2025 | Intrarosa, Femlyv, Femring |
| Glaxosmithkline, LLC. | $28.28 | 2022-2023 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $25.31 | 2020 | |
| Azurity Pharmaceuticals, INC. | $18.33 | 2023 | Adthyza |
| Stryker Corporation | $17.77 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2024 | Trintellix |
| Mylan Pharmaceuticals INC. | $15.47 | 2022 | |
| Minerva Surgical, INC | $13.90 | 2022 | |
| Merck Sharp & Dohme LLC | $13.53 | 2024 | Gardasil 9, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.